Verastem, Inc.

Good morning and welcome to Verisim Oncology's third quarter 2025 earnings conference call. My name is Liz and I'll be your call operator for today. Please note this event is being recorded. All participants will be in a listen-only mode. After today's presentation, there will be an opportunity to ask questions. I will now turn the call over to Julissa Vianna, Vice President of Corporate Communications, Investor Relations, and Patient Advocacy at Verisim Oncology. Please go ahead.

Thank you, Operator. Welcome, everyone, and thank you for joining us today to discuss Verisim's third quarter 2025 financial results and recent business updates. This morning, we issued a press release detailing our financial results for the quarter and year to date. This release, along with the slide presentation that we will reference during our call today, are available on our website. Before we begin, I would like to remind you that any statements made during this call are not historical and are considered to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these statements as a result of various important factors, including those discussed in the risk factors section in the company's most recent annual report on Form 10-K, filed with the SEC on March 20, 2025, and the current report on Form 10-Q that will be filed later today, as well as other reports filed with the SEC. Any forward-looking statements we make represent Verisim's views as of today, and we disclaim any obligations or responsibilities to update. Joining me on today's call are Dan Patterson, President and Chief Executive Officer of Veristem, who will provide opening remarks and recap key highlights from the quarter. Matt Ross, Chief Operating Officer, and Mike Crowther, Chief Commercial Officer, who will walk through the continued progress of the Avnatsky Vaxinja Copac commercial launch. And Dan Calkins, Chief Financial Officer, who will provide an overview of our financial results. I will now turn the call over to Dan.

Thank you, Julissa. Good morning and thank you for joining us today to discuss our third quarter financial results and business update. In Q2, we shared our excitement about achieving FDA approval for abmapgifaxin jacopac and KRAS-mutated recurrent low-grade serous ovarian cancer, or LGSOC, and reported our first six weeks of commercial performance. Today, I'm pleased to share that the strength we saw in those initial weeks has accelerated. With a full quarter of commercial operations now complete, the fundamentals we put in place to guide our commercial launch are translating into meaningful results. Our third quarter net product revenue of $11.2 million surpassed our expectations and was driven by consistent adoption among both academic centers and community oncologists. We set three key objectives to support our commercial execution and drive sustainable growth. physician engagement, patient initiation and retention, and streamlined reimbursement. All three are trending positively. We're simultaneously advancing our broader strategic priorities, specifically expanding the opportunity set for ABMAP defect syndrome COPAQ and accelerating the clinical path of ZS7375, our KRAS G12D on-off inhibitor program. Let me highlight a few achievements. We completed the enrollment of our expansion cohort in RAMP 205, our first-line pancreatic cancer trial, evaluating avutamatinib plus difactinib and standard-of-care chemotherapy. We completed the planned enrollment of our confirmatory Phase III clinical trial, RAMP 301, in recurrent LGSOC, and we'll be making a modest increase in enrollment per the IDMC's recommendation. This does not have a meaningful impact on our expected timelines. We shared initial safety and tolerability data from our G12D program, the VS7375. We cleared two monotherapy doses with no dose-limiting toxicities. We reported that we did not observe nausea, vomiting, or diarrhea above grade one. Importantly, these dose levels included the Phase II go-forward dose that was chosen by our partner in China. We're now moving ahead, opening the combination cohort with cetuximab. These are exciting developments that add to our continued success. In the fourth quarter, we remain focused on our three key launch objectives and maintaining our execution discipline across all commercial, clinical, and operational functions. Let me now turn the call over to Matt to review some specific highlights from the third quarter.